Targets for Kidney Fibrosis

Understanding the molecular targets implicated in kidney fibrosis is critical for elucidating the complex pathogenic mechanisms underlying this chronic and progressive disease. Kidney fibrosis is characterized by excessive deposition of extracellular matrix (ECM) components, leading to structural disorganization, loss of renal function, and ultimately, end-stage renal disease. The targets identified here represent a diverse array of mechanistic pathways, including G protein-coupled receptor signaling, renin-angiotensin system modulation, lipid mediator biosynthesis, transcriptional and epigenetic regulation, ECM synthesis, and oxidative stress response. Collectively, these targets provide a multifaceted view of the disease, revealing key nodes that drive fibroblast activation, myofibroblast differentiation, inflammation, and ECM accumulation. By dissecting the contribution of each target to these core pathogenic processes, researchers can identify novel therapeutic opportunities—ranging from small molecule inhibitors to biologics and gene therapies—aimed at halting or reversing fibrosis. Furthermore, several of these molecules serve as potential biomarkers for disease progression and treatment response, supporting both drug development and clinical management. Strategic targeting of these pathways has the potential to transform the treatment landscape for kidney fibrosis, which currently lacks effective disease-modifying therapies.

Gpcr And Renin-Angiotensin System Modulators

This category includes targets that modulate G protein-coupled receptor (GPCR) signaling and the renin-angiotensin system, both of which are directly implicated in the initiation and progression of kidney fibrosis. These targets regulate key processes such as inflammation, vasoconstriction, fibroblast activation, and ECM deposition. The main targets in this category are Adenosine A3 Receptor (ADORA3) and Angiotensin II Receptor Type 2 (AGTR2), both of which have well-characterized roles in renal fibrogenesis.

Adenosine A3 Receptor (ADORA3)

Adenosine A3 Receptor (ADORA3) is a G protein-coupled receptor with a seven-transmembrane domain structure, primarily coupling to Gi proteins to inhibit adenylate cyclase and modulate cAMP levels. It is regulated by extracellular adenosine concentrations, which increase in hypoxic or inflammatory conditions typical of kidney injury. ADORA3 activation has been shown to promote pro-fibrotic signaling, including the induction of TGF-β and connective tissue growth factor (CTGF/CCN2), leading to fibroblast activation and ECM production. Experimental models demonstrate that selective antagonism of ADORA3 attenuates renal fibrosis, while agonism exacerbates fibrotic responses. These findings highlight ADORA3 as a potential therapeutic target, with several small molecule antagonists in preclinical development. Its expression correlates with disease severity, suggesting biomarker potential (Entrez: 140, KEGG: 140, UniProt: P0DMS8).

Angiotensin II Receptor Type 2 (AGTR2)

Angiotensin II Receptor Type 2 (AGTR2) is a GPCR with seven transmembrane domains, primarily expressed in the renal vasculature, interstitium, and during injury. AGTR2 signaling generally counteracts the pro-fibrotic, hypertensive, and pro-inflammatory effects of AGTR1, but its exact role in kidney fibrosis is context-dependent. In some models, AGTR2 activation suppresses fibrosis by inhibiting myofibroblast differentiation and promoting anti-inflammatory pathways (e.g., nitric oxide, cGMP). However, AGTR2 can also drive apoptosis of tubular cells and contribute to maladaptive repair. AGTR2 is regulated by angiotensin II levels and receptor heterodimerization. Pharmacological modulation of AGTR2 is under investigation, with selective agonists and antagonists showing variable anti-fibrotic efficacy (Entrez: 186, KEGG: 186, UniProt: P50052).

Lipid Mediator Enzymes And Oxidative Stress

This category includes enzymes involved in the biosynthesis and metabolism of lipid mediators and oxidative stress response, which are directly implicated in the pathogenesis of kidney fibrosis. These targets regulate inflammatory signaling, leukocyte recruitment, and cellular redox balance, all of which contribute to fibrogenesis. Key targets here are Arachidonate 5-Lipoxygenase (ALOX5), Cytochrome P450 Family 4 Subfamily A Member 11 (CYP4A11), Cytochrome P450 Family 4 Subfamily F Member 2 (CYP4F2), and Epoxide Hydrolase 2 (EPHX2).

Arachidonate 5-Lipoxygenase (ALOX5)

Arachidonate 5-Lipoxygenase (ALOX5) is a non-heme iron-containing enzyme responsible for the conversion of arachidonic acid to leukotriene A4, a precursor of pro-inflammatory leukotrienes. Structurally, it contains a C2-like domain and a catalytic domain. ALOX5 is regulated by calcium, phosphorylation, and interaction with FLAP (5-lipoxygenase-activating protein). In kidney fibrosis, ALOX5-derived leukotrienes promote leukocyte infiltration, fibroblast activation, and ECM deposition. Genetic or pharmacological inhibition of ALOX5 reduces renal fibrosis in animal models. Several ALOX5 inhibitors (e.g., zileuton) have shown anti-fibrotic effects in preclinical studies, and ALOX5 expression correlates with disease activity (Entrez: 240, KEGG: 240, UniProt: P09917).

Cytochrome P450 Family 4 Subfamily A Member 11 (CYP4A11)

Cytochrome P450 Family 4 Subfamily A Member 11 (CYP4A11) is a monooxygenase enzyme involved in the ω-hydroxylation of fatty acids, including the production of 20-HETE, a bioactive lipid mediator. The protein contains a typical P450 heme-binding domain. CYP4A11 is regulated by peroxisome proliferator-activated receptors (PPARs) and substrate availability. In kidney fibrosis, 20-HETE promotes vasoconstriction, inflammation, and tubular injury, all contributing to fibrogenesis. CYP4A11 overexpression has been linked to increased susceptibility to renal fibrosis, whereas inhibition reduces fibrotic progression in experimental models. CYP4A11 is emerging as a target for small molecule inhibitors and potential biomarker for disease progression (Entrez: 1579, KEGG: 1579, UniProt: Q02928).

Cytochrome P450 Family 4 Subfamily F Member 2 (CYP4F2)

Cytochrome P450 Family 4 Subfamily F Member 2 (CYP4F2) is another member of the P450 superfamily, catalyzing the ω-hydroxylation of leukotriene B4 and other bioactive lipids. It contains the conserved P450 heme domain and is regulated by inflammatory cytokines and lipid substrates. CYP4F2 modulates both pro- and anti-inflammatory lipid mediators, influencing the inflammatory milieu of the fibrotic kidney. Genetic polymorphisms in CYP4F2 have been associated with altered risk of renal fibrosis and progression of chronic kidney disease. Inhibitors of CYP4F2 are under investigation for their anti-inflammatory and anti-fibrotic effects (Entrez: 8529, KEGG: 8529, UniProt: P78329).

Epoxide Hydrolase 2 (EPHX2)

Epoxide Hydrolase 2 (EPHX2) is a bifunctional enzyme with an N-terminal lipid phosphatase and a C-terminal epoxide hydrolase domain. It converts anti-inflammatory and anti-fibrotic epoxyeicosatrienoic acids (EETs) into less active dihydroxyeicosatrienoic acids (DHETs). EPHX2 is regulated by oxidative stress and inflammatory stimuli. Increased EPHX2 activity is observed in fibrotic kidneys, leading to reduced EET bioavailability and exacerbation of fibrosis. EPHX2 inhibitors (e.g., GSK2256294A) are in preclinical and early clinical development for fibrotic diseases, with evidence of reduced ECM deposition and improved renal function in animal models (Entrez: 2053, KEGG: 2053, UniProt: P34913).

Transcriptional And Epigenetic Regulators

This category includes factors that regulate gene expression and chromatin structure, directly influencing the transcriptional programs that drive fibroblast activation, myofibroblast differentiation, and ECM production in kidney fibrosis. The main targets are Bromodomain Containing 4 (BRD4) and Serum Response Factor (SRF), both of which modulate pro-fibrotic gene networks.

Bromodomain Containing 4 (BRD4)

Bromodomain Containing 4 (BRD4) is a member of the BET (bromodomain and extraterminal) family, possessing two N-terminal bromodomains that recognize acetylated lysine residues on histones and a C-terminal ET domain for protein-protein interactions. BRD4 acts as an epigenetic reader, recruiting transcriptional machinery to pro-fibrotic gene promoters, including those for collagen and TGF-β pathway components. BRD4 is upregulated in fibrotic kidneys, and its inhibition (e.g., with JQ1) suppresses myofibroblast activation and ECM gene transcription in vitro and in vivo. BRD4 is a validated target for anti-fibrotic drug development, with several BET inhibitors in early-phase clinical trials for fibrotic and inflammatory diseases (Entrez: 23476, KEGG: 23476, UniProt: O60885).

Serum Response Factor (SRF)

Serum Response Factor (SRF) is a MADS-box transcription factor that binds to serum response elements (SREs) in the promoters of immediate-early and cytoskeletal genes. SRF forms complexes with co-factors such as myocardin-related transcription factors (MRTFs). In kidney fibrosis, SRF is activated by RhoA-mediated actin polymerization and TGF-β signaling, driving the expression of α-smooth muscle actin (α-SMA), collagens, and other myofibroblast markers. Genetic ablation or pharmacological inhibition of SRF or its co-activators reduces fibrosis in experimental models. SRF is a potential biomarker for myofibroblast activation and disease progression (Entrez: 6722, KEGG: 6722, UniProt: P11831).

Extracellular Matrix And Fibroblast Activation

This category encompasses targets that directly regulate extracellular matrix (ECM) production, fibroblast activation, and cell-matrix interactions, which are central to the development and progression of kidney fibrosis. The principal targets are Cellular Communication Network Factor 2 (CCN2/CTGF) and Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1).

Cellular Communication Network Factor 2 (CCN2)

Cellular Communication Network Factor 2 (CCN2), also known as Connective Tissue Growth Factor (CTGF), is a secreted matricellular protein with four functional domains (IGFBP, VWC, TSP1, and CT). CCN2 is induced by TGF-β and other pro-fibrotic stimuli. It binds to integrins, growth factors, and ECM components, promoting fibroblast proliferation, myofibroblast differentiation, and collagen synthesis. CCN2 is consistently overexpressed in fibrotic kidneys, and its inhibition (e.g., with monoclonal antibodies such as pamrevlumab) reduces ECM accumulation and preserves renal function in preclinical and clinical studies. CCN2 is a validated biomarker and therapeutic target for kidney fibrosis (Entrez: 1490, KEGG: 1490, UniProt: P29279).

Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1)

Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1) is a receptor tyrosine kinase with an extracellular discoidin domain that binds to collagens and a cytoplasmic kinase domain. DDR1 is activated by collagen deposition in the ECM, leading to downstream signaling that enhances fibroblast survival, migration, and further ECM synthesis. DDR1 is upregulated in fibrotic kidneys and its genetic deletion or pharmacological inhibition attenuates fibrosis in animal models. DDR1 inhibitors are in early-stage development for fibrotic diseases (Entrez: 780, KEGG: 780, UniProt: Q08345).

Redox Regulation And Cellular Stress Response

This category includes targets that regulate oxidative stress and cellular redox balance, which are key drivers of tubular injury, inflammation, and fibrogenesis in the kidney. The main disease-relevant target is Kelch Like ECH Associated Protein 1 (KEAP1), which modulates the NRF2 antioxidant pathway.

Kelch Like ECH Associated Protein 1 (KEAP1)

Kelch Like ECH Associated Protein 1 (KEAP1) is a cytoplasmic protein with multiple kelch and BTB domains, acting as a substrate adaptor for CUL3 ubiquitin ligase and regulating the degradation of NRF2, a master antioxidant transcription factor. Under oxidative stress, KEAP1 is inactivated, allowing NRF2 to translocate to the nucleus and induce expression of cytoprotective genes. In kidney fibrosis, excessive KEAP1 activity suppresses NRF2 signaling, exacerbating oxidative damage and promoting fibroblast activation. KEAP1 inhibitors or NRF2 activators have shown promise in reducing renal fibrosis in preclinical models. KEAP1 is a potential biomarker and therapeutic target for redox modulation in kidney disease (Entrez: 9817, KEGG: 9817, UniProt: Q14145).